News

Number of news items returned: 41 to 60 records of 397

"CaroMel's platform launch set"

27 October 2017

(3762 views)

"CaroMel's platform launch set   Platform launch CaroMel’s platform is ready for launch. The company will now sprint to load the branding and ...

"We are launching any day now" CaroMel Ltd Podcast

19 October 2017

(4106 views)

    "We are launching any day now"   Podcast: Listen as Raghu Rajakumar spoke to Greg McLardie, Managing Director of CaroMel Ltd. CaroMel is ...

LeenLife signs Agreement with BioCube

17 October 2017

(4147 views)

  LeenLife Pharma International: Production and Operations in North America Exclusivity Agreement with BioCubeTM   "October 17, 2017 CSE - LLP The Company is pleased to ...

Mining, Cars and Cyber Protection - Funding Strategies Connect September 2017

06 October 2017

(3655 views)

  Dear Reader,   In discussing our services with prospects and clients, it is important to be clear on their company's strategic objectives. Quite ...

CaroMel - Director Briefing with Greg McLardie

03 October 2017

(4049 views)

  Director Briefing with Greg McLardie, CaroMel Ltd   “Our digital platform allows orders to be received from and shipped directly to the ...

Haixi - Extension of the Offer Period

28 September 2017

(3970 views)

  Haixi - Extension of the Offer Period   "The Board of Directors of Haixi Pharmaceutical International Holdings Limited (ACN 616 806 574) ...

CaroMel's platform launch set

26 September 2017

(3767 views)

CaroMel's platform launch set "CaroMel's digital platform is on track to launch within three months with the technology build, traceability and ...

"CaroMel plans 2018 IPO for global expansion of agritech marketplace - MD"

22 September 2017

(3379 views)

  "CaroMel plans 2018 IPO for global expansion of agritech marketplace - MD"   "CaroMel, an Australian digital agritech marketplace, plans to list ...

CaroMel completes minimum subscription prior to launch

19 September 2017

(3498 views)

  CaroMel completes minimum subscription prior to launch "On behalf of our team, I am delighted to announce CaroMel has completed the ...

Venture Capital updates and other news - Funding Strategies Connect August 2017

01 September 2017

(3699 views)

 Venture Capital updates and other news - Funding Strategies Connect August 2017 Dear Readers, I attended the AVCAL / Future Fund Venture ...

Project 'Glucose Biosensor'

30 August 2017

(5324 views)

  Project 'Glucose Biosensor'     Click here to watch the Project 'Glucose Biosensor' video. This is a first to market, first in class ...

CaroMel Ltd

30 August 2017

(5332 views)

   CaroMel Ltd – A digital disruption enabling fishermen and farmers to connect directly with high-end restaurants in China CaroMel Ltd aims to ...

Take a look at the new Nifty Forms site!

30 August 2017

(3664 views)

Take a look at the new Nifty Forms site!   "See how the new Nifty Forms site will make claiming R&D easier If ...

"The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage"

30 August 2017

(4011 views)

  "The Tooth Booth Business Model Delivers A Much Better GP Margin Percentage   The Tooth Booth Board is pleased to announce that ...

CXi Announces Second Client for Unit Registry

29 August 2017

(3998 views)

   CXi Announces Second Client for Unit Registry   "CXi Software (“CXi”) has announced that it has successfully migrated its second client, in ...

Invest in the first Chinese pharmaceutical company to list on the ASX: Haixi

22 August 2017

(4821 views)

  Invest in the first Chinese pharmaceutical company to list on the ASX: Haixi Pharmaceutical International Holdings Limited ASX: HXP   Dear Readers, I invite ...

Lobster, Diabetes, Dental and Unit Registries - Funding Strategies Connect July 2017

27 July 2017

(4562 views)

  Lobster, Diabetes, Dental and Unit Registries - Funding Strategies Connect July 2017   Dear Readers, Its been an exciting and interesting month since ...

Podcast: Filling the Gap in the Market (ft. Darren Berry from The Tooth Booth)

26 July 2017

(4589 views)

  Podcast: Filling the Gap in the Market (ft. Darren Berry from The Tooth Booth)   "Summary In this episode of Eden Exchanges we ...

CXi - "The Xero of unit registries" - signs first client

26 July 2017

(4636 views)

  CXi - "The Xero of unit registries" - signs first client      "New Australian fintech CXi Software Pty Ltd (CXi) announces that ...

Tooth Booth: Exceeds Forecast | In Negotiations with Coomera

25 July 2017

(4529 views)

  Tooth Booth: Exceeds Forecast | In Negotiations with Coomera   "The Tooth Booth Board are pleased to announce that the forecasted figures ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625